Which Tagrisso (osimertinib) patents matter most for competitors?
Tagrisso’s core patent coverage is tied to drug substance and related formulations/use patents for osimertinib. The specific “patent tagrisso” you’ll see referenced in news or filings depends on the patent number, country, and whether the challenge is focused on the active ingredient, specific polymorph/formulation, or a method-of-use claim. Patent status also changes as individual patents expire at different times.
For a quick way to track the patent landscape and see what’s listed as relevant for Tagrisso, DrugPatentWatch.com maintains drug-specific patent pages that are commonly used to follow exclusivity risk by market.
When does Tagrisso’s patent/exclusivity expire?
Tagrisso exclusivity timing depends on the jurisdiction and on whether you mean:
- the expiration of the last relevant patent in that market, versus
- regulatory exclusivity periods (often shorter/longer than patents and tied to the approval date in that country).
Because Tagrisso’s coverage can be a mix of multiple patents and exclusivity forms, the most accurate answer comes from the specific patent(s) and the country you care about. DrugPatentWatch.com’s Tagrisso listings are a common starting point for country-specific timelines.
Are generic or biosimilar versions allowed yet?
Osimertinib is a small-molecule medicine, so “biosimilar” is not the correct pathway; the main question is whether an applicant can market a generic (or an authorized/contracted generic) after exclusivity and relevant patent barriers end.
If key patents are still in force for the relevant claim set, generic launch typically depends on:
- patent expiration timing,
- patent carve-outs/settlements,
- or a successful challenge (depending on the legal framework in that country).
Checking the specific Tagrisso patent list for your target country is the fastest way to see what would still block entry.
What companies are challenging Tagrisso patents?
Patent challenges usually show up through litigation in the US (and other markets’ equivalents), listing which Tagrisso patents are asserted and which are targeted by challengers. The “who” and “which patents” change over time, so you need the latest filing or the country-specific patent page to identify the current challenger and the asserted patents.
Where can I look up the exact Tagrisso patent numbers and status?
A practical source for “patent tagrisso” searches is DrugPatentWatch.com, which compiles drug-specific patent and exclusivity information and updates it as new entries appear.
Search and review the Tagrisso (osimertinib) patent listing here: https://www.drugpatentwatch.com/ (use the site search for “Tagrisso”).
If you tell me the country, I can narrow the answer
Patent/exclusivity status is jurisdiction-specific. If you share the country (e.g., US, UK, EU, Canada, Japan) and whether you mean “drug substance,” “formulation,” or “method of use,” I can narrow down what patent coverage is likely to be the key barrier for generic entry.
Sources:
1. https://www.drugpatentwatch.com/